Scinovex
review Open AccessTop 10% cited

GI Epidemiology: nonalcoholic fatty liver disease

Alimentary Pharmacology & Therapeutics · 2007 · Vol. 25(8) · pp. 883–889

Abstract

To review the data available on the epidemiology and natural history of NAFLD as well as the risk factors for its development and the areas where future research is necessary. RESULTS /CONCLUSIONS: NAFLD may affect individuals of any age range and race/ethnicity. NAFLD affects one in three adults and one in ten children/adolescents in the United States. Mortality in patients with NAFLD is significantly higher than in the general population of same age and gender with liver-related complications being a common cause of death. Liver-related morbidity and mortality in NAFLD occurs when the disease has progressed to advanced fibrosis and cirrhosis. Further studies are necessary to determine the impact of NAFLD on health-related quality of life and resources utilization, and to the extent to which preventing the development of the metabolic syndrome would prevent NAFLD development and reduce liver-related morbidity and mortality. Lifestyle intervention may improve NAFLD, but medications that increase insulin sensitivity and the antioxidant defenses in the liver deserve evaluation in carefully controlled trials.

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseasePancreatitis Pathology and TreatmentNonalcoholic fatty liver diseaseMedicineCirrhosisEpidemiologyMetabolic syndromeInsulin resistanceInternal medicineDiseaseLiver diseasePopulation

MeSH terms

Fatty LiverFemaleHumansMaleObesityRisk FactorsGlobal HealthPrevalenceDisease Progression
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.